Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

Appointment of New Executive Officer

On August 2, 2021, G1 Therapeutics, Inc. (the "Company") announced the appointment of Andrew Perry as Chief Commercial Officer. Mr. Perry joins the Company from ViiV Healthcare NA, a joint venture majority-owned by GlaxoSmithKline, where he served as Vice President, US Marketing. Mr. Perry brings nearly 25 years of leadership experience in product commercialization and managed markets to the Company, having led multiple successful product launches and growing brands.

Departure of Executive Officer

On July 27, 2021, the Company and Soma Gupta, Chief Commercial Officer, mutually agreed to separate. Ms. Gupta left the Company for personal and professional reasons.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits



Exhibit No.       Description

99.1                Press Release dated August 2, 2021

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses